ArticleNucleic acids research2026
SynCraft: an integrated web server for ADMET-aware retrosynthesis and molecular design.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The efficient design of drug candidates requires simultaneous consideration of synthetic feasibility and pharmacokinetic safety. However, current computational tools typically address retrosynthetic planning and ADMET evaluation as separate tasks, requiring users to manually transfer data between platforms and evaluate candidate molecules in a sequential and time-consuming manner. Here, we present SynCraft, a web server that integrates template-based retrosynthesis with real-time ADMET evaluation within a unified workflow. SynCraft accepts molecular input via SMILES, interactive drawing, or file upload, and performs automated multi-step retrosynthetic planning while simultaneously assessing the safety and drug-likeness of all intermediate compounds. ADMET properties are predicted using a multi-view learning framework, and potentially hazardous intermediates are automatically highlighted with intuitive, colour-coded warnings during route exploration. The server further provides integrated analysis tools, including synthetic accessibility and complexity scoring, drug-likeness evaluation, and interactive 2D/3D visualization, enabling users to seamlessly transition from route generation to detailed molecular assessment. Results are presented through an interactive interface that allows comparison of alternative synthetic routes, with downloadable outputs in standard formats. In a case study of imatinib, SynCraft automatically identifies genotoxic intermediates that are typically overlooked in conventional retrosynthesis workflows, demonstrating its practical utility for safety-aware route design. The web server is freely accessible at https://syncraft.denglab.org.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.